Trial Outcomes & Findings for A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NCT NCT03207867)

NCT ID: NCT03207867

Last Updated: 2024-10-09

Results Overview

ORR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR), based on local investigator assessment per Response Evaluation Criteria for Solid Tumors (RECIST) v1.1. For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

315 participants

Primary outcome timeframe

Up to 3.9 years

Results posted on

2024-10-09

Participant Flow

Participants took part in 21 investigative sites in 15 countries.

The screening period began once patients had signed the study informed consent. Screening evaluations had to be completed within 21 days prior to the first dose of treatment except for the radiological tumor assessment which had to be performed within 28 days prior to the first dose. After screening, the treatment period started on Cycle 1 Day 1.

Participant milestones

Participant milestones
Measure	Part 1: RCC naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: H-N Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: MSS CRC Unk 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with unknown RAS status	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had not been previously treated with immuno-oncology therapy	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: DLBCL 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL)	Part 1: DLBCL 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Overall Study STARTED	11	12	11	14	14	15	11	12	27	29	2	30	3	13	13	6	15	22	20	20	6	3	3	3
Overall Study COMPLETED	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Overall Study NOT COMPLETED	11	12	11	14	14	15	11	12	27	29	2	30	3	13	13	6	15	22	20	20	6	3	3	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: RCC naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: H-N Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: MSS CRC Unk 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with unknown RAS status	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had not been previously treated with immuno-oncology therapy	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: DLBCL 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL)	Part 1: DLBCL 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Overall Study Adverse Event	1	0	1	0	0	2	1	1	2	2	0	0	0	0	0	0	3	1	2	1	0	0	0	0
Overall Study Death	0	0	0	0	0	1	0	3	1	2	0	1	0	1	0	0	0	2	0	1	0	0	0	0
Overall Study Physician Decision	3	5	0	3	2	0	0	0	4	2	0	4	0	0	2	1	1	2	1	3	0	0	0	0
Overall Study Progressive Disease	7	7	9	10	11	10	9	8	19	23	2	24	3	11	9	5	10	14	13	14	6	3	3	3
Overall Study Patient/guardian Decision	0	0	1	1	1	2	1	0	1	0	0	1	0	1	2	0	1	3	4	1	0	0	0	0

Baseline Characteristics

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=11 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: H-N Pre 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=29 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: MSS CRC Unk 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with unknown RAS status	Part 1: TNBC 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma naïve 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had not been previously treated with immuno-oncology therapy	Part 1: Melanoma Pre 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: DLBCL 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL)	Part 1: DLBCL 240 mg n=6 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL)	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg Cont n=22 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 Participants NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 Participants NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont n=3 Participants NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont n=3 Participants NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in	Total n=315 Participants Total of all reporting groups
Race/Ethnicity, Customized White	9 Participants n=5 Participants	3 Participants n=7 Participants	10 Participants n=5 Participants	13 Participants n=4 Participants	5 Participants n=21 Participants	14 Participants n=10 Participants	9 Participants n=115 Participants	12 Participants n=24 Participants	20 Participants n=42 Participants	23 Participants n=42 Participants	2 Participants n=42 Participants	21 Participants n=42 Participants	1 Participants n=36 Participants	13 Participants n=36 Participants	7 Participants n=24 Participants	0 Participants n=135 Participants	13 Participants n=136 Participants	10 Participants n=44 Participants	7 Participants n=667 Participants	7 Participants n=7 Participants	1 Participants n=6 Participants	0 Participants n=10 Participants	0 Participants n=14 Participants	0 Participants n=4 Participants	200 Participants n=4 Participants
Age, Continuous	65.5 years STANDARD_DEVIATION 10.86 • n=5 Participants	60.0 years STANDARD_DEVIATION 11.96 • n=7 Participants	60.6 years STANDARD_DEVIATION 8.54 • n=5 Participants	60.4 years STANDARD_DEVIATION 8.98 • n=4 Participants	66.9 years STANDARD_DEVIATION 9.63 • n=21 Participants	61.6 years STANDARD_DEVIATION 7.13 • n=10 Participants	59.4 years STANDARD_DEVIATION 9.05 • n=115 Participants	60.2 years STANDARD_DEVIATION 7.07 • n=24 Participants	56.5 years STANDARD_DEVIATION 9.04 • n=42 Participants	58.1 years STANDARD_DEVIATION 11.21 • n=42 Participants	46.0 years STANDARD_DEVIATION 15.56 • n=42 Participants	49.8 years STANDARD_DEVIATION 10.81 • n=42 Participants	50.3 years STANDARD_DEVIATION 20.65 • n=36 Participants	54.2 years STANDARD_DEVIATION 14.87 • n=36 Participants	55.0 years STANDARD_DEVIATION 18.65 • n=24 Participants	61.5 years STANDARD_DEVIATION 13.10 • n=135 Participants	68.3 years STANDARD_DEVIATION 8.14 • n=136 Participants	65.0 years STANDARD_DEVIATION 9.02 • n=44 Participants	61.8 years STANDARD_DEVIATION 9.51 • n=667 Participants	64.2 years STANDARD_DEVIATION 8.94 • n=7 Participants	58.5 years STANDARD_DEVIATION 16.16 • n=6 Participants	61.3 years STANDARD_DEVIATION 10.69 • n=10 Participants	57.0 years STANDARD_DEVIATION 9.54 • n=14 Participants	44.3 years STANDARD_DEVIATION 8.33 • n=4 Participants	59.5 years STANDARD_DEVIATION 11.59 • n=4 Participants
Sex: Female, Male Female	3 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	6 Participants n=4 Participants	5 Participants n=21 Participants	2 Participants n=10 Participants	3 Participants n=115 Participants	3 Participants n=24 Participants	9 Participants n=42 Participants	8 Participants n=42 Participants	1 Participants n=42 Participants	30 Participants n=42 Participants	1 Participants n=36 Participants	3 Participants n=36 Participants	7 Participants n=24 Participants	3 Participants n=135 Participants	0 Participants n=136 Participants	7 Participants n=44 Participants	7 Participants n=667 Participants	8 Participants n=7 Participants	6 Participants n=6 Participants	3 Participants n=10 Participants	1 Participants n=14 Participants	1 Participants n=4 Participants	119 Participants n=4 Participants
Sex: Female, Male Male	8 Participants n=5 Participants	12 Participants n=7 Participants	9 Participants n=5 Participants	8 Participants n=4 Participants	9 Participants n=21 Participants	13 Participants n=10 Participants	8 Participants n=115 Participants	9 Participants n=24 Participants	18 Participants n=42 Participants	21 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=36 Participants	10 Participants n=36 Participants	6 Participants n=24 Participants	3 Participants n=135 Participants	15 Participants n=136 Participants	15 Participants n=44 Participants	13 Participants n=667 Participants	12 Participants n=7 Participants	0 Participants n=6 Participants	0 Participants n=10 Participants	2 Participants n=14 Participants	2 Participants n=4 Participants	196 Participants n=4 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	0 Participants n=7 Participants	0 Participants n=6 Participants	3 Participants n=10 Participants	3 Participants n=14 Participants	3 Participants n=4 Participants	10 Participants n=4 Participants
Race/Ethnicity, Customized Asian	2 Participants n=5 Participants	8 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	8 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	6 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	2 Participants n=36 Participants	0 Participants n=36 Participants	4 Participants n=24 Participants	6 Participants n=135 Participants	2 Participants n=136 Participants	11 Participants n=44 Participants	13 Participants n=667 Participants	12 Participants n=7 Participants	0 Participants n=6 Participants	0 Participants n=10 Participants	0 Participants n=14 Participants	0 Participants n=4 Participants	78 Participants n=4 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	0 Participants n=7 Participants	0 Participants n=6 Participants	0 Participants n=10 Participants	0 Participants n=14 Participants	0 Participants n=4 Participants	1 Participants n=4 Participants
Race/Ethnicity, Customized Other	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	1 Participants n=44 Participants	0 Participants n=667 Participants	0 Participants n=7 Participants	3 Participants n=6 Participants	0 Participants n=10 Participants	0 Participants n=14 Participants	0 Participants n=4 Participants	5 Participants n=4 Participants
Race/Ethnicity, Customized Unknown	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	1 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	5 Participants n=42 Participants	0 Participants n=42 Participants	7 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	2 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants	0 Participants n=44 Participants	0 Participants n=667 Participants	1 Participants n=7 Participants	2 Participants n=6 Participants	0 Participants n=10 Participants	0 Participants n=14 Participants	0 Participants n=4 Participants	21 Participants n=4 Participants

PRIMARY outcome

Timeframe: Up to 3.9 years

Population: All patients from Part 1 who received at least 1 full or partial dose of assigned combination of study drugs and were included in the selected advanced solid tumors groups defined in the study protocol for efficacy assessment: RCC naïve 160 mg, RCC naïve 240 mg, RCC pre 240 mg, pancreatic 160 mg, urothelial 160 mg, H-N naïve 160 mg, H-N pre 160 mg, MSS CRC wt 160 mg, MSS CRC mu 160 mg, TNBC 160 mg, melanoma pre 160 mg and mCRPC 240 mg

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=11 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=29 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Overall Response Rate (ORR) Per RECIST v1.1 for Solid Tumors	27.3 percentage of participants Interval 7.9 to 56.4	25.0 percentage of participants Interval 7.2 to 52.7	0 percentage of participants Interval 0.0 to 23.8	0 percentage of participants Interval 0.0 to 19.3	7.1 percentage of participants Interval 0.4 to 29.7	13.3 percentage of participants Interval 2.4 to 36.3	0 percentage of participants Interval 0.0 to 23.8	0 percentage of participants Interval 0.0 to 10.5	3.4 percentage of participants Interval 0.2 to 15.3	10.0 percentage of participants Interval 2.8 to 23.9	0 percentage of participants Interval 0.0 to 20.6	0 percentage of participants Interval 0.0 to 18.1	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to 2.5 years

Population: All patients from Part 1 who received at least 1 full or partial dose of assigned combination of study drugs and were included in the selected lymphoma group defined in the study protocol for efficacy assessment: DLBCL 160 mg

ORR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR), based on local investigator assessment per Cheson 2014 criteria for diffuse large B-cell lymphoma (DLBCL). For Cheson 2014 criteria, CR= Target nodes/nodal masses must regress to ≤1.5 cm in longest diameter (LDi), no extralymphatic sites of disease, absent non-measured lesions, organ enlargement regress to normal, no new lesions, and bone marrow normal by morphology (if indeterminate, immunohistochemistry negative); PR= ≥50% decrease in the sum of the product of the perpendicular diameters (SPD) of up to 6 target measurable nodes, absent or regressed non-measured lesions, spleen must have regressed by \>50% in length beyond normal, and no new lesions.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Overall Response Rate (ORR) Per Cheson 2014 for DLBCL	15.4 percentage of participants Interval 2.8 to 41.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to 4.7 years

Population: All patients from Part 2 who were randomized to the study treatment dosing schedule.

ORR is the percentage of patients with a best overall response of complete response (CR) or partial response (PR), based on local investigator assessment per RECIST v1.1. For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=22 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Overall Response Rate (ORR) Per RECIST v1.1 for Solid Tumors	9.1 percentage of participants Interval 1.6 to 25.9	0 percentage of participants Interval 0.0 to 13.9	10.0 percentage of participants Interval 1.8 to 28.3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to 0.5 years

Population: All patients from Part 3 who received at least 1 full or partial dose of assigned combination of study drugs.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Overall Response Rate (ORR) Per RECIST v1.1 for Solid Tumors	16.7 percentage of participants Interval 0.9 to 58.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years

ORR is the percentage of patients with a best overall response of complete response (iCR) or partial response (iPR), based on local investigator assessment per immune-related RECIST (iRECIST).

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=11 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=29 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Overall Response Rate (ORR) Per iRECIST for Solid Tumors	36.4 percentage of participants Interval 13.5 to 65.0	25.0 percentage of participants Interval 7.2 to 52.7	0 percentage of participants Interval 0.0 to 23.8	0 percentage of participants Interval 0.0 to 19.3	7.1 percentage of participants Interval 0.4 to 29.7	13.3 percentage of participants Interval 2.4 to 36.3	0 percentage of participants Interval 0.0 to 23.8	0 percentage of participants Interval 0.0 to 10.5	3.4 percentage of participants Interval 0.2 to 15.3	10.0 percentage of participants Interval 2.8 to 23.9	0 percentage of participants Interval 0.0 to 20.6	0 percentage of participants Interval 0.0 to 18.1	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 4.7 years

Population: All patients from Part 2 who were randomized to the study treatment dosing schedule.

ORR is the percentage of patients with a best overall response of complete response (iCR) or partial response (iPR), based on local investigator assessment per immune-related RECIST (iRECIST).

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=22 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Overall Response Rate (ORR) Per iRECIST for Solid Tumors	9.1 percentage of participants Interval 1.6 to 25.9	5.0 percentage of participants Interval 0.3 to 21.6	15.0 percentage of participants Interval 4.2 to 34.4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 0.5 years

Population: All patients from Part 3 who received at least 1 full or partial dose of assigned combination of study drugs.

ORR is the percentage of patients with a best overall response of complete response (iCR) or partial response (iPR), based on local investigator assessment per immune-related RECIST (iRECIST).

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Overall Response Rate (ORR) Per iRECIST for Solid Tumors	16.7 percentage of participants Interval 0.9 to 58.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline, up to 0.8 years

Population: All patients from Part 1 who received at least 1 full or partial dose of assigned combination of study drugs and were included in the prostate cancer group defined in the study protocol for efficacy assessment: mCRPC 240 mg

Prostate-specific antigen (PSA) levels were assessed in serum. Rising PSA is generally a manifestation of progression of prostate cancer.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Mean Percentage Change in PSA From Baseline	214.46 percentage change in PSA from baseline Standard Deviation 329.459	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years

DCR is the percentage of patients with a best overall response of complete response (CR), partial response (PR), stable disease (SD) or Non-CR or Non-progressive disease (NCRNPD), based on local investigator assessment per Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=11 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=29 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Disease Control Rate (DCR) Per RECIST v1.1 for Solid Tumors	54.5 percentage of participants Interval 27.1 to 80.0	66.7 percentage of participants Interval 39.1 to 87.7	18.2 percentage of participants Interval 3.3 to 47.0	0 percentage of participants Interval 0.0 to 19.3	28.6 percentage of participants Interval 10.4 to 54.0	40.0 percentage of participants Interval 19.1 to 64.0	63.6 percentage of participants Interval 35.0 to 86.5	25.9 percentage of participants Interval 12.9 to 43.2	17.2 percentage of participants Interval 7.0 to 32.9	33.3 percentage of participants Interval 19.3 to 49.9	0 percentage of participants Interval 0.0 to 20.6	46.7 percentage of participants Interval 24.4 to 70.0	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years

DCR is the percentage of patients with a best overall response of complete response (iCR), partial response (iPR), stable disease (iSD) or Non-iCR or Non-unconfirmed progressive disease (NON-iCR or NON-iUPD), based on local investigator assessment per immune-related RECIST (iRECIST).

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=11 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=29 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Disease Control Rate (DCR) Per iRECIST for Solid Tumors	63.6 percentage of participants Interval 35.0 to 86.5	66.7 percentage of participants Interval 39.1 to 87.7	18.2 percentage of participants Interval 3.3 to 47.0	0 percentage of participants Interval 0.0 to 19.3	35.7 percentage of participants Interval 15.3 to 61.0	40.0 percentage of participants Interval 19.1 to 64.0	54.5 percentage of participants Interval 27.1 to 80.0	25.9 percentage of participants Interval 12.9 to 43.2	13.8 percentage of participants Interval 4.9 to 28.8	36.7 percentage of participants Interval 22.1 to 53.3	0 percentage of participants Interval 0.0 to 20.6	46.7 percentage of participants Interval 24.4 to 70.0	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 2.5 years

DCR is the percentage of patients with a best overall response of complete response (CR), partial response (PR) or stable disease (SD), based on local investigator assessment per Cheson 2014 criteria for diffuse large B-cell lymphoma (DLBCL).

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Disease Control Rate (DCR) Per Cheson 2014 for DLBCL	23.1 percentage of participants Interval 6.6 to 49.5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 4.7 years

Population: All patients from Part 2 who were randomized to the study treatment dosing schedule.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=22 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Disease Control Rate (DCR) Per RECIST v1.1 for Solid Tumors	36.4 percentage of participants Interval 19.6 to 56.1	40.0 percentage of participants Interval 21.7 to 60.6	35.0 percentage of participants Interval 17.7 to 55.8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 4.7 years

Population: All patients from Part 2 who were randomized to the study treatment dosing schedule.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=22 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Disease Control Rate (DCR) Per iRECIST for Solid Tumors	36.4 percentage of participants Interval 19.6 to 56.1	45.0 percentage of participants Interval 25.9 to 65.3	45.0 percentage of participants Interval 25.9 to 65.3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 0.5 years

Population: All patients from Part 3 who received at least 1 full or partial dose of assigned combination of study drugs.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Disease Control Rate (DCR) Per RECIST v1.1 for Solid Tumors	16.7 percentage of participants Interval 0.9 to 58.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 0.5 years

Population: All patients from Part 3 who received at least 1 full or partial dose of assigned combination of study drugs.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Disease Control Rate (DCR) Per iRECIST for Solid Tumors	16.7 percentage of participants Interval 0.9 to 58.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years

Population: All patients from Part 1 for whom best overall response was CR or PR and were included in the selected advanced solid tumors groups defined in the study protocol for efficacy assessment: RCC naïve 160 mg, RCC naïve 240 mg, RCC pre 240 mg, pancreatic 160 mg, urothelial 160 mg, H-N naïve 160 mg, H-N pre 160 mg, MSS CRC wt 160 mg, MSS CRC mu 160 mg, TNBC 160 mg, melanoma pre 160 mg and mCRPC 240 mg

DOR only applies to patients for whom best overall response is complete response (CR) or partial response (PR) based on local investigator assessment per RECIST v1.1. DOR is defined as the time from the date of first documented response (CR or PR) to the date of first documented progression or death due to underlying cancer. If a patient did not have an event, DOR was censored at the date of last adequate tumor assessment. DOR was analyzed using Kaplan-Meier estimates as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Duration Of Response (DOR) Per RECIST v1.1 for Solid Tumors	NA months Not estimable due to insufficient number of participants with events	NA months Not estimable due to insufficient number of participants with events	—	—	NA months Not estimable due to insufficient number of participants with events	NA months Not estimable due to insufficient number of participants with events	—	—	NA months Not estimable due to insufficient number of participants with events	NA months Not estimable due to insufficient number of participants with events	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years

Population: All patients from Part 1 for whom best overall response was iCR or iPR and were included in the selected advanced solid tumors groups defined in the study protocol for efficacy assessment: RCC naïve 160 mg, RCC naïve 240 mg, RCC pre 240 mg, pancreatic 160 mg, urothelial 160 mg, H-N naïve 160 mg, H-N pre 160 mg, MSS CRC wt 160 mg, MSS CRC mu 160 mg, TNBC 160 mg, melanoma pre 160 mg and mCRPC 240 mg

DOR only applies to patients for whom best overall response is complete response (iCR) or partial response (iPR) based on local investigator assessment per iRECIST. DOR is defined as the time from the date of first documented response (iCR or iPR) to the date of first documented progression or death due to underlying cancer. If a patient did not have an event, DOR was censored at the date of last adequate tumor assessment. DOR was analyzed using Kaplan-Meier estimates as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=4 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Duration Of Response (DOR) Per iRECIST for Solid Tumors	NA months Not estimable due to insufficient number of participants with events	NA months Not estimable due to insufficient number of participants with events	—	—	NA months Not estimable due to insufficient number of participants with events	NA months Not estimable due to insufficient number of participants with events	—	—	NA months Not estimable due to insufficient number of participants with events	NA months Not estimable due to insufficient number of participants with events	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 2.5 years

Population: All patients from Part 1 for whom best overall response was CR or PR and were included in the selected lymphoma group defined in the study protocol for efficacy assessment: DLBCL 160 mg

DOR only applies to patients for whom best overall response is complete response (CR) or partial response (PR) based on local investigator assessment per Cheson 2014 criteria for DLBCL. DOR is defined as the time from the date of first documented response (CR or PR) to the date of first documented progression or death due to underlying cancer. If a patient did not have an event, DOR was censored at the date of last adequate tumor assessment. DOR was analyzed using Kaplan-Meier estimates as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Duration Of Response (DOR) Per Cheson 2014 for DLBCL	NA months Not estimable due to insufficient number of participants with events	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 4.7 years

Population: All patients from Part 2 for whom best overall response was CR or PR

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=2 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Duration Of Response (DOR) Per RECIST v1.1 for Solid Tumors	NA months Not estimable due to insufficient number of participants with events	—	NA months Not estimable due to insufficient number of participants with events	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 4.7 years

Population: All patients from Part 2 for whom best overall response was iCR or iPR

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=1 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Duration Of Response (DOR) Per iRECIST for Solid Tumors	NA months Not estimable due to insufficient number of participants with events	NA months Not estimable due to insufficient number of participants with events	NA months Not estimable due to insufficient number of participants with events	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 0.5 years

Population: All patients from Part 3 for whom best overall response was CR or PR

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Duration Of Response (DOR) Per RECIST v1.1 for Solid Tumors	NA months Not estimable due to insufficient number of participants with events	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 0.5 years

Population: All patients from Part 3 for whom best overall response was iCR or iPR

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Duration Of Response (DOR) Per iRECIST for Solid Tumors	NA months Not estimable due to insufficient number of participants with events	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years

PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause, whichever happened first. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. Tumor response was based on local investigator assessment per RECIST v1.1. PFS was analyzed using Kaplan-Meier estimates as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=11 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=29 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Progression-Free Survival (PFS) Per RECIST v1.1 for Solid Tumors	3.5 months Interval 1.9 to 15.4	7.2 months Interval 1.8 to 8.6	1.9 months Interval 1.7 to 2.0	1.7 months Interval 1.6 to 1.7	1.9 months Interval 1.7 to 3.5	2.0 months Interval 1.6 to 3.7	3.5 months Interval 1.7 to 3.7	1.7 months Interval 1.6 to 1.9	1.9 months Interval 1.7 to 2.0	1.7 months Interval 1.6 to 1.9	1.8 months Interval 1.6 to 1.9	3.7 months Interval 1.7 to 5.3	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years

PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause, whichever happened first. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. Tumor response was based on local investigator assessment per iRECIST. PFS was analyzed using Kaplan-Meier estimates as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=11 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=29 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Progression-Free Survival (PFS) Per iRECIST for Solid Tumors	8.7 months Interval 2.1 to Not estimable due to insufficient number of participants with events	7.2 months Interval 1.8 to Not estimable due to insufficient number of participants with events	1.9 months Interval 1.7 to 2.0	1.7 months Interval 1.1 to 1.7	2.1 months Interval 1.7 to 3.5	2.0 months Interval 1.6 to 3.7	3.5 months Interval 1.7 to 3.7	1.8 months Interval 1.6 to 2.0	1.9 months Interval 1.7 to 2.0	1.8 months Interval 1.6 to 3.5	1.8 months Interval 1.6 to 1.9	3.7 months Interval 1.7 to 5.3	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 2.5 years

PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause, whichever happened first. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. Tumor response was based on local investigator assessment per Cheson 2014 for DLBCL. PFS was analyzed using Kaplan-Meier estimates as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Progression-Free Survival (PFS) Per Cheson 2014 for DLBCL	1.7 months Interval 1.4 to 2.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 4.7 years

Population: All patients from Part 2 who were randomized to the study treatment dosing schedule.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=22 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Progression-Free Survival (PFS) Per RECIST v1.1 for Solid Tumors	2.0 months Interval 1.8 to 3.8	2.1 months Interval 1.7 to 3.7	1.9 months Interval 1.7 to 3.7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 4.7 years

Population: All patients from Part 2 who were randomized to the study treatment dosing schedule.

PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause, whichever happened first. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. Tumor response was based on local investigator assessment per iRECIST. PFS was analyzed using Kaplan-Meier estimates as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=22 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Progression-Free Survival (PFS) Per iRECIST for Solid Tumors	2.1 months Interval 1.8 to 3.8	2.2 months Interval 1.8 to 3.7	2.8 months Interval 1.7 to 9.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 0.5 years

Population: All patients from Part 3 who received at least 1 full or partial dose of assigned combination of study drugs.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Progression-Free Survival (PFS) Per RECIST v1.1 for Solid Tumors	1.6 months Interval 0.9 to 1.8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 0.5 years

Population: All patients from Part 3 who received at least 1 full or partial dose of assigned combination of study drugs.

PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause, whichever happened first. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. Tumor response was based on local investigator assessment per iRECIST. PFS was analyzed using Kaplan-Meier estimates as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Progression-Free Survival (PFS) Per iRECIST for Solid Tumors	1.6 months Interval 0.9 to 1.8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 2 years

Population: All patients from Part 1 who received at least 1 full or partial dose of assigned combination of study drugs and were included in the selected cancer groups defined in the protocol for efficacy assessment: RCC naïve 160 mg, RCC naïve 240 mg, RCC pre 240 mg, pancreatic 160 mg, urothelial 160 mg, H-N naïve 160 mg, H-N pre 160 mg, MSS CRC wt 160 mg, MSS CRC mu 160 mg, TNBC 160 mg, melanoma pre 160 mg, DLBCL 160 mg and mCRPC 240 mg

OS represents the percentage of participants who are alive after the start of study treatment. OS at 2 years was estimated using the Kaplan-Meier method as defined in the statistical analysis plan (SAP).

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=11 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=15 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=29 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=13 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: 2-year Overall Survival (OS)	63.6 percentage of participants Interval 35.5 to 82.1	42.1 percentage of participants Interval 14.6 to 67.8	27.3 percentage of participants Interval 8.9 to 49.8	NA percentage of participants Not estimable due to insufficient number of participants with events	36.1 percentage of participants Interval 15.0 to 57.9	33.3 percentage of participants Interval 15.0 to 52.9	15.3 percentage of participants Interval 1.9 to 41.2	22.1 percentage of participants Interval 9.4 to 38.2	14.3 percentage of participants Interval 4.3 to 29.9	30.8 percentage of participants Interval 16.0 to 46.9	NA percentage of participants Not estimable due to insufficient number of participants with events	23.1 percentage of participants Interval 7.5 to 43.6	31.4 percentage of participants Interval 10.8 to 54.7	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 2 years

Population: All patients from Part 2 who were randomized to the study treatment dosing schedule.

OS represents the percentage of participants who are alive after the start of study treatment. OS at 2 years was estimated using the Kaplan-Meier method as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=22 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: 2-year Overall Survival (OS)	33.6 percentage of participants Interval 15.5 to 52.9	22.7 percentage of participants Interval 7.5 to 42.7	39.7 percentage of participants Interval 20.3 to 58.6	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 2 years

Population: All patients from Part 3 who received at least 1 full or partial dose of assigned combination of study drugs.

OS represents the percentage of participants who are alive after the start of study treatment. OS at 2 years was estimated using the Kaplan-Meier method as defined in the statistical analysis plan.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: 2-year Overall Survival (OS)	NA percentage of participants Not estimable due to insufficient number of participants with events	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Screening and on-treatment (Cycle 2 Day 1 or Day 15). The duration of one cycle was 28 days.

Population: All patients from Part 1 who received any study drug, had paired tumor samples, had a valid assessment for the outcome measure and were included in the selected cancer groups defined in the protocol for efficacy assessment: RCC naïve 160 mg, RCC naïve 240 mg, RCC pre 240 mg, pancreatic 160 mg, urothelial 160 mg, H-N naïve 160 mg, H-N pre 160 mg, MSS CRC wt 160 mg, MSS CRC mu 160 mg, TNBC 160 mg, melanoma pre 160 mg, DLBCL 160 mg and mCRPC 240 mg

The tumor expression of CD8 was measured by immunohistochemical (IHC) methods. Newly obtained pre- and on-treatment paired tumor samples were required and collected at screening and after approximately two cycles of therapy.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=5 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=5 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=4 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=7 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=9 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=10 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=4 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=1 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=4 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1: Change From Baseline in CD8 Percent Marker Area in Tumor Tissue	10.93 CD8 percent marker area Standard Deviation 14.227	10.53 CD8 percent marker area Standard Deviation 12.456	0.70 CD8 percent marker area Standard Deviation 2.645	-0.81 CD8 percent marker area Standard Deviation 0.537	0.96 CD8 percent marker area Standard Deviation 1.345	1.63 CD8 percent marker area Standard Deviation 2.372	-0.42 CD8 percent marker area Standard Deviation 1.477	0.70 CD8 percent marker area Standard Deviation 1.141	-0.01 CD8 percent marker area Standard Deviation 1.164	4.86 CD8 percent marker area Standard Deviation 3.751	0.16 CD8 percent marker area Standard Deviation 0.540	7.84 CD8 percent marker area	2.67 CD8 percent marker area Standard Deviation 4.156	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Screening and on-treatment (Cycle 2 Day 1 or Day 15). The duration of one cycle was 28 days.

Population: All patients from Part 2 who received any study drug, had paired tumor samples and had a valid assessment for the outcome measure

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=4 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=4 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 2: Change From Baseline in CD8 Percent Marker Area in Tumor Tissue	3.81 CD8 percent marker area Standard Deviation 4.551	-2.35 CD8 percent marker area Standard Deviation 5.586	1.23 CD8 percent marker area Standard Deviation 2.955	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Screening and on-treatment (Cycle 2 Day 1 or Day 15). The duration of one cycle was 28 days.

Population: All patients from Part 3 who received any study drug, had paired tumor samples and had a valid assessment for the outcome measure

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 3: Change From Baseline in CD8 Percent Marker Area in Tumor Tissue	0.26 CD8 percent marker area	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 4 years (Part 1), 4.8 years (Part 2) and 0.6 years (Part 3)

Population: All patients from Part 1, 2 and 3 who received at least 1 dose of NIR178 or PDR001. For the safety endpoints, patients at each study part with the same type of cancer who are treated at the same dose level and dosing schedule are pooled together, independently of the immune-oncology (IO) pretreatment status and RAS mutation status.

Number of participants with AEs (any AE regardless of seriousness) and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs. The on-treatment period is defined from the day of first administration of study treatment up to 30 days after the date of its last administration.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=23 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=14 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=26 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=12 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=58 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=16 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=22 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 Participants NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 Participants NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1, 2 and 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period SAEs	3 Participants	7 Participants	9 Participants	7 Participants	15 Participants	5 Participants	28 Participants	11 Participants	3 Participants	6 Participants	0 Participants	4 Participants	11 Participants	7 Participants	7 Participants	3 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period Treatment-related SAEs	0 Participants	2 Participants	2 Participants	1 Participants	3 Participants	2 Participants	7 Participants	2 Participants	0 Participants	2 Participants	0 Participants	2 Participants	6 Participants	3 Participants	0 Participants	0 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period Fatal SAEs	1 Participants	0 Participants	1 Participants	0 Participants	2 Participants	1 Participants	3 Participants	1 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period AEs	10 Participants	22 Participants	14 Participants	14 Participants	26 Participants	12 Participants	57 Participants	29 Participants	15 Participants	13 Participants	5 Participants	14 Participants	22 Participants	18 Participants	18 Participants	6 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period Treatment-related AEs	7 Participants	16 Participants	9 Participants	9 Participants	16 Participants	9 Participants	34 Participants	23 Participants	6 Participants	11 Participants	2 Participants	12 Participants	15 Participants	14 Participants	9 Participants	4 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period Treatment-related fatal SAEs	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years (Part 1), 4.7 years (Part 2) and 0.5 years (Part 3)

Number of participants with at least one dose reduction of NIR178 and number of participants with at least one dose interruption of NIR178. Dose or schedule adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=23 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=14 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=26 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=12 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=58 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=16 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=22 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 Participants NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 Participants NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1, 2 and 3: Number of Participants With Dose Reductions and Dose Interruptions of NIR178 At least one dose reduction	2 Participants	1 Participants	0 Participants	2 Participants	8 Participants	1 Participants	7 Participants	3 Participants	1 Participants	1 Participants	0 Participants	2 Participants	2 Participants	1 Participants	1 Participants	0 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Dose Reductions and Dose Interruptions of NIR178 At least one dose interruption	6 Participants	9 Participants	2 Participants	8 Participants	12 Participants	3 Participants	20 Participants	9 Participants	3 Participants	3 Participants	1 Participants	5 Participants	8 Participants	5 Participants	4 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years (Part 1), 4.7 years (Part 2) and 0.5 years (Part 3)

Number of participants with at least one dose reduction of PDR001 and number of participants with at least one dose interruption of PDR001. Dose or schedule adjustments were permitted for patients who did not tolerate the protocol-specified dosing schedule. Dose reductions were not permitted for PDR001.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=23 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=14 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=26 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=12 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=58 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=16 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=22 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 Participants NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 Participants NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1, 2 and 3: Number of Participants With Dose Reductions and Dose Interruptions of PDR001 At least one dose interruption	6 Participants	7 Participants	1 Participants	6 Participants	9 Participants	1 Participants	13 Participants	8 Participants	2 Participants	0 Participants	0 Participants	2 Participants	6 Participants	4 Participants	2 Participants	0 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Dose Reductions and Dose Interruptions of PDR001 At least one dose reduction	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years (Part 1), 4.7 years (Part 2) and 0.5 years (Part 3)

Dose intensity of NIR178 was calculated as cumulative actual dose in milligrams divided by duration of exposure in days.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=23 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=14 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=26 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=12 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=58 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=16 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=22 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 Participants NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 Participants NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1, 2 and 3: Dose Intensity of NIR178	316.7 mg/day Interval 187.0 to 320.0	477.3 mg/day Interval 321.0 to 480.0	320.0 mg/day Interval 241.0 to 320.0	295.7 mg/day Interval 140.0 to 320.0	309.8 mg/day Interval 141.0 to 320.0	480.0 mg/day Interval 272.0 to 480.0	320.0 mg/day Interval 134.0 to 320.0	320.0 mg/day Interval 179.0 to 320.0	320.0 mg/day Interval 208.0 to 320.0	320.0 mg/day Interval 233.0 to 320.0	480.0 mg/day Interval 363.0 to 480.0	480.0 mg/day Interval 382.0 to 496.0	320.0 mg/day Interval 137.0 to 320.0	160.0 mg/day Interval 96.0 to 173.0	160.0 mg/day Interval 71.0 to 189.0	320.0 mg/day Interval 319.0 to 320.0	—	—	—

SECONDARY outcome

Timeframe: Up to 3.9 years (Part 1), 4.7 years (Part 2) and 0.5 years (Part 3)

Dose intensity of PDR001 was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and then multiplied by 28 days.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=23 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=14 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=26 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=12 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=58 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=16 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=22 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 Participants NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 Participants NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1, 2 and 3: Dose Intensity of PDR001	394.2 mg/28 days Interval 300.0 to 400.0	396.2 mg/28 days Interval 267.0 to 431.0	400.0 mg/28 days Interval 395.0 to 400.0	393.1 mg/28 days Interval 350.0 to 400.0	398.2 mg/28 days Interval 319.0 to 402.0	400.0 mg/28 days Interval 365.0 to 407.0	400.0 mg/28 days Interval 236.0 to 405.0	400.0 mg/28 days Interval 305.0 to 404.0	400.0 mg/28 days Interval 389.0 to 406.0	400.0 mg/28 days Interval 386.0 to 400.0	400.0 mg/28 days Interval 400.0 to 400.0	400.0 mg/28 days Interval 378.0 to 404.0	400.0 mg/28 days Interval 224.0 to 406.0	400.0 mg/28 days Interval 300.0 to 401.0	400.0 mg/28 days Interval 387.0 to 410.0	400.0 mg/28 days Interval 400.0 to 400.0	—	—	—

SECONDARY outcome

Timeframe: Up to approximately 5 years

Population: All patients from Part 1, 2 and 3 who received at least 1 dose of NIR178 or PDR001 and had a determinant baseline immunogenicity (IG) sample and at least 1 determinant post-baseline IG sample for assessing anti-PDR001 antibodies. For the safety endpoints, patients at each study part with the same type of cancer who are treated at the same dose level and dosing schedule are pooled together, independently of the immune-oncology (IO) pretreatment status and RAS mutation status.

PDR001 immunogenicity was evaluated in serum samples. Patient anti-drug antibodies (ADA) status was defined as follows: * ADA-negative at baseline: ADA-negative sample at baseline * ADA-positive at baseline: ADA-positive sample at baseline * ADA-negative post-baseline: ADA-negative sample at baseline and at least 1 post-baseline sample, all of which are ADA-negative samples * Treatment-reduced ADA-positive: ADA-positive sample at baseline and at least 1 post-baseline sample, all of which are ADA-negative samples * Treatment-induced ADA-positive: ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample * Treatment-boosted ADA-positive: ADA-positive sample at baseline and at least 1 treatment-boosted ADA-positive sample * ADA-inconclusive: patient who does not qualify for any of the above definitions or a patient for which the baseline sample is missing

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=23 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=12 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=24 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=52 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=27 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=10 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=13 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=21 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=19 Participants NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=17 Participants NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Part 1, 2 and 3: Number of Participants With Anti-PDR001 Antibodies ADA-negative at baseline	11 Participants	23 Participants	12 Participants	13 Participants	24 Participants	11 Participants	49 Participants	27 Participants	13 Participants	10 Participants	6 Participants	13 Participants	21 Participants	19 Participants	17 Participants	6 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Anti-PDR001 Antibodies ADA-positive at baseline	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	3 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Anti-PDR001 Antibodies ADA-negative post-baseline	10 Participants	23 Participants	11 Participants	12 Participants	22 Participants	11 Participants	48 Participants	25 Participants	13 Participants	10 Participants	6 Participants	11 Participants	21 Participants	14 Participants	14 Participants	5 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Anti-PDR001 Antibodies Treatment-reduced ADA-positive	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Anti-PDR001 Antibodies Treatment-induced ADA-positive	1 Participants	0 Participants	1 Participants	1 Participants	2 Participants	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	5 Participants	3 Participants	1 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Anti-PDR001 Antibodies Treatment-boosted ADA-positive	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—
Part 1, 2 and 3: Number of Participants With Anti-PDR001 Antibodies ADA-inconclusive	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	—	—	—

SECONDARY outcome

Timeframe: 28 days

Population: All patients in the Japan safety run-in who either met the minimum exposure criterion defined in the protocol and had sufficient safety evaluations, or had experienced a DLT during Cycle 1.

A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications, which occurs within the first 28 days of treatment with NIR178 as single agent or in combination with PDR001 during the Japan safety run-in part of the study. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Japan Safety Run-in: Number of Participants With Dose-Limiting Toxicities (DLTs)	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Up to 0.7 years

Population: All patients from the Japan safety run-in who received at least 1 dose of NIR178 or PDR001.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
Japan Safety Run-in: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period AEs	3 Participants	3 Participants	3 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Japan Safety Run-in: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period Treatment-related AEs	0 Participants	2 Participants	1 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Japan Safety Run-in: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period SAEs	2 Participants	1 Participants	1 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Japan Safety Run-in: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period Treatment-related SAEs	0 Participants	1 Participants	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Japan Safety Run-in: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period Fatal SAEs	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Japan Safety Run-in: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period Treatment-related fatal SAEs	0 Participants	0 Participants	0 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1 Day 1 (all), Cycle 1 Day 7 (1wk-on/1wk-off), Cycle 1 Day 14 (2wk-on/2wk-off) and Cycle 1 Day 28 (continuous dosing): pre-dose, 15 and 30 minutes, 1, 1.5, 2, 3, 4 and 8 hours after morning dose and 12 hours after evening dose. 1 cycle=28 days

Population: Patients in the pharmacokinetic analysis set (PAS) who received NIR178 and had an available value for the outcome measure at each timepoint. PAS consists of all patients who received one of the planned treatments, provided at least one PK parameter and did not vomit within 4 hours after dosing with NIR178. Patients from the same ethnicity (Non-Japanese, Japanese) treated with the same formulation (capsule, tablet) at the same NIR178 dose level are pooled together.

Pharmacokinetic (PK) parameters were calculated based on NIR178 plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed plasma concentration following a dose.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=206 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=54 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=6 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Maximum Observed Plasma Concentration (Cmax) of NIR178 Cycle 1 Day 1 (all regimens)	129 ng/mL Geometric Coefficient of Variation 335.0	160 ng/mL Geometric Coefficient of Variation 247.8	75.1 ng/mL Geometric Coefficient of Variation 382.3	81.8 ng/mL Geometric Coefficient of Variation 99.9	30.1 ng/mL Geometric Coefficient of Variation 32.9	234 ng/mL Geometric Coefficient of Variation 70.9	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Maximum Observed Plasma Concentration (Cmax) of NIR178 Cycle 1 Day 7 (1 wk-on/1 wk-off)	576 ng/mL Geometric Coefficient of Variation 83.1	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Maximum Observed Plasma Concentration (Cmax) of NIR178 Cycle 1 Day 14 (2 wk-on/2 wk-off)	392 ng/mL Geometric Coefficient of Variation 212.7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Maximum Observed Plasma Concentration (Cmax) of NIR178 Cycle 1 Day 28 (continuous)	297 ng/mL Geometric Coefficient of Variation 291.4	622 ng/mL Geometric Coefficient of Variation 154.3	723 ng/mL Geometric Coefficient of Variation 295.5	311 ng/mL Geometric Coefficient of Variation 91.5	167 ng/mL Geometric Coefficient of Variation 40.9	3760 ng/mL Geometric Coefficient of Variation 39.6	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Pharmacokinetic (PK) parameters were calculated based on NIR178 plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) plasma concentration following a dose. Actual recorded sampling times were considered for the calculations.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=206 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=54 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=6 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Time to Reach Maximum Plasma Concentration (Tmax) of NIR178 Cycle 1 Day 1 (all regimens)	2.00 hours Interval 0.25 to 8.0	2.13 hours Interval 0.5 to 8.0	1.50 hours Interval 0.45 to 4.05	1.50 hours Interval 1.47 to 1.5	1.50 hours Interval 0.583 to 3.95	3.00 hours Interval 2.03 to 3.03	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Time to Reach Maximum Plasma Concentration (Tmax) of NIR178 Cycle 1 Day 7 (1 wk-on/1 wk-off)	1.45 hours Interval 0.5 to 4.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Time to Reach Maximum Plasma Concentration (Tmax) of NIR178 Cycle 1 Day 14 (2 wk-on/2 wk-off)	1.97 hours Interval 0.55 to 7.67	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Time to Reach Maximum Plasma Concentration (Tmax) of NIR178 Cycle 1 Day 28 (continuous)	2.00 hours Interval 0.267 to 8.0	2.02 hours Interval 0.25 to 7.6	1.52 hours Interval 0.5 to 3.0	1.43 hours Interval 0.5 to 1.48	1.45 hours Interval 0.5 to 1.5	2.87 hours Interval 1.92 to 4.0	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

PK parameters were calculated based on NIR178 plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUC0-12hr calculation.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=95 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=24 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=4 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC0-12hr) of NIR178 Cycle 1 Day 1 (all regimens)	295 hr*ng/mL Geometric Coefficient of Variation 198.3	487 hr*ng/mL Geometric Coefficient of Variation 126.3	232 hr*ng/mL Geometric Coefficient of Variation 437.4	170 hr*ng/mL Geometric Coefficient of Variation 124.9	63.3 hr*ng/mL Geometric Coefficient of Variation 88.0	550 hr*ng/mL	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC0-12hr) of NIR178 Cycle 1 Day 7 (1 wk-on/1 wk-off)	1260 hr*ng/mL Geometric Coefficient of Variation 63.2	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC0-12hr) of NIR178 Cycle 1 Day 14 (2 wk-on/2 wk-off)	1680 hr*ng/mL Geometric Coefficient of Variation 94.4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC0-12hr) of NIR178 Cycle 1 Day 28 (continuous)	918 hr*ng/mL Geometric Coefficient of Variation 187.5	1620 hr*ng/mL Geometric Coefficient of Variation 147.9	938 hr*ng/mL Geometric Coefficient of Variation 412.2	697 hr*ng/mL Geometric Coefficient of Variation 131.8	242 hr*ng/mL Geometric Coefficient of Variation 13.5	12800 hr*ng/mL	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

NJI765 is a NIR178 metabolite. PK parameters were calculated based on NJI765 plasma concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed plasma concentration following a dose.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=201 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=54 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=6 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Maximum Observed Plasma Concentration (Cmax) of NJI765 (NIR178 Metabolite) Cycle 1 Day 1 (all regimens)	25.5 ng/mL Geometric Coefficient of Variation 85.2	33.7 ng/mL Geometric Coefficient of Variation 64.2	20.1 ng/mL Geometric Coefficient of Variation 99.2	—	25.9 ng/mL Geometric Coefficient of Variation 77.0	28.5 ng/mL Geometric Coefficient of Variation 99.9	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Maximum Observed Plasma Concentration (Cmax) of NJI765 (NIR178 Metabolite) Cycle 1 Day 7 (1 wk-on/1 wk-off)	62.9 ng/mL Geometric Coefficient of Variation 39.4	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Maximum Observed Plasma Concentration (Cmax) of NJI765 (NIR178 Metabolite) Cycle 1 Day 14 (2 wk-on/2 wk-off)	71.3 ng/mL Geometric Coefficient of Variation 43.3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Maximum Observed Plasma Concentration (Cmax) of NJI765 (NIR178 Metabolite) Cycle 1 Day 28 (continuous)	42.6 ng/mL Geometric Coefficient of Variation 82.2	77.3 ng/mL Geometric Coefficient of Variation 49.9	54.1 ng/mL Geometric Coefficient of Variation 102.4	45.6 ng/mL Geometric Coefficient of Variation 74.0	53.9 ng/mL Geometric Coefficient of Variation 64.2	111 ng/mL Geometric Coefficient of Variation 36.6	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

NJI765 is a NIR178 metabolite. Pharmacokinetic (PK) parameters were calculated based on NJI765 plasma concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) plasma concentration following a dose. Actual recorded sampling times were considered for the calculations.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=201 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=54 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=6 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=2 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Time to Reach Maximum Plasma Concentration (Tmax) of NJI765 (NIR178 Metabolite) Cycle 1 Day 1 (all regimens)	2.00 hours Interval 0.25 to 8.05	2.08 hours Interval 0.5 to 8.0	2.10 hours Interval 0.45 to 4.05	—	1.95 hours Interval 0.583 to 2.0	3.00 hours Interval 2.03 to 3.03	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Time to Reach Maximum Plasma Concentration (Tmax) of NJI765 (NIR178 Metabolite) Cycle 1 Day 7 (1 wk-on/1 wk-off)	1.50 hours Interval 0.5 to 4.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Time to Reach Maximum Plasma Concentration (Tmax) of NJI765 (NIR178 Metabolite) Cycle 1 Day 14 (2 wk-on/2 wk-off)	1.98 hours Interval 0.55 to 3.0	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Time to Reach Maximum Plasma Concentration (Tmax) of NJI765 (NIR178 Metabolite) Cycle 1 Day 28 (continuous)	2.00 hours Interval 0.483 to 8.03	2.10 hours Interval 0.25 to 7.88	0.750 hours Interval 0.5 to 2.03	2.23 hours Interval 1.43 to 3.02	1.45 hours Interval 0.5 to 1.5	2.87 hours Interval 1.92 to 4.0	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

NJI765 is a NIR178 metabolite. PK parameters were calculated based on NJI765 plasma concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUC0-12hr calculation.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=62 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=20 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=2 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=1 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC0-12hr) of NJI765 (NIR178 Metabolite) Cycle 1 Day 1 (all regimens)	98.2 hr*ng/mL Geometric Coefficient of Variation 87.1	122 hr*ng/mL Geometric Coefficient of Variation 75.6	77.1 hr*ng/mL Geometric Coefficient of Variation 35.9	—	117 hr*ng/mL Geometric Coefficient of Variation 68.2	119 hr*ng/mL	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC0-12hr) of NJI765 (NIR178 Metabolite) Cycle 1 Day 7 (1 wk-on/1 wk-off)	243 hr*ng/mL Geometric Coefficient of Variation 57.5	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC0-12hr) of NJI765 (NIR178 Metabolite) Cycle 1 Day 14 (2 wk-on/2 wk-off)	288 hr*ng/mL Geometric Coefficient of Variation 23.7	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC0-12hr) of NJI765 (NIR178 Metabolite) Cycle 1 Day 28 (continuous)	214 hr*ng/mL Geometric Coefficient of Variation 76.6	382 hr*ng/mL Geometric Coefficient of Variation 43.7	226 hr*ng/mL Geometric Coefficient of Variation 147.0	—	277 hr*ng/mL Geometric Coefficient of Variation 69.0	362 hr*ng/mL	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: First dose (Cycle 1 Day 1 or Cycle 2 Day 1 for Japanese patients treated with NIR178 80 or 160 mg) and Cycle 3 Day 1: pre-infusion, 1, 168, 336, 504 and 672 hours after end of infusion. Average duration of infusion=30 minutes. 1 cycle=28 days

Population: Patients in the pharmacokinetic analysis set (PAS) who received PDR001 and had an available value for the outcome measure at each timepoint. PAS consists of all patients who received one of the planned treatments, provided at least one PK parameter and did not vomit within 4 hours after dosing with NIR178. Patients from the same ethnicity (Non-Japanese, Japanese) treated at the same PDR001 dose level are pooled together.

PK parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=257 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Maximum Observed Serum Concentration (Cmax) of PDR001 First dose (Cycle 1 Day 1 or Cycle 2 Day 1)	93.2 µg/mL Geometric Coefficient of Variation 30.8	85.0 µg/mL Geometric Coefficient of Variation 12.8	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Maximum Observed Serum Concentration (Cmax) of PDR001 Cycle 3 Day 1	126 µg/mL Geometric Coefficient of Variation 37.4	119 µg/mL	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

PK parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) serum concentration following a dose. Actual recorded sampling times were considered for the calculations.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=257 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Time to Reach Maximum Serum Concentration (Tmax) of PDR001 First dose (Cycle 1 Day 1 or Cycle 2 Day 1)	1.50 hours Interval 0.333 to 718.0	1.50 hours Interval 1.48 to 1.52	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Time to Reach Maximum Serum Concentration (Tmax) of PDR001 Cycle 3 Day 1	1.50 hours Interval 0.55 to 358.0	1.65 hours Interval 1.65 to 1.65	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

PK parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUC0-28day calculation.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=236 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=3 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All Study Parts: Area Under the Serum Concentration-time Curve From Time Zero to 28 Days Post Dose (AUC0-28day) of PDR001 First dose (Cycle 1 Day 1 or Cycle 2 Day 1)	1140 day*µg/mL Geometric Coefficient of Variation 31.2	1110 day*µg/mL Geometric Coefficient of Variation 13.9	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
All Study Parts: Area Under the Serum Concentration-time Curve From Time Zero to 28 Days Post Dose (AUC0-28day) of PDR001 Cycle 3 Day 1	2030 day*µg/mL Geometric Coefficient of Variation 41.3	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

POST_HOC outcome

Timeframe: On-treatment and safety follow-up (FU) deaths: up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Survival FU deaths: up to 4.3 years (Part 1), 5.1 years (Part 2) and 0.9 years (Part 3) and 0.9 years (JSR)

Population: All patients who received at least one dose of study treatment. Patients at each study part with the same type of cancer who are treated at the same dose level and dosing schedule are pooled together, independently of the immune-oncology (IO) pretreatment status and RAS mutation status.

On-treatment and post-treatment safety follow-up deaths were collected from first dose of study medication to 150 days after last dose of NIR178+PDR001. Survival follow-up deaths were collected from 151 days after last dose of NIR178+PDR001 until end of study. All deaths refer to the sum of on-treatment and post-treatment safety follow-up deaths plus survival follow-up deaths.

Outcome measures

Outcome measures
Measure	Part 1: RCC naïve 160 mg n=11 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC naïve 240 mg n=23 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy	Part 1: RCC Pre 240 mg n=14 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had been pretreated with immuno-oncology therapy	Part 1: Pancreatic 160 mg n=14 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer	Part 1: Urothelial 160 mg n=26 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer	Part 1: H-N naïve 160 mg n=12 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had not been previously treated with immuno-oncology therapy	Part 1: H-N Pre 160 mg n=58 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy	Part 1: MSS CRC wt 160 mg n=30 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS wildtype	Part 1: MSS CRC mu 160 mg n=16 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) with RAS mutant	Part 1: TNBC 160 mg n=13 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	Part 1: Melanoma Pre 160 mg n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma who had been pretreated with immuno-oncology therapy	Part 1: mCRPC 240 mg n=15 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 1: mCRPC 240 mg n=22 Participants NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC)	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 Participants NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 Participants NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC)	Part 3: TNBC 160 mg Cont n=6 Participants NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC)	JSR: 80 mg Cont n=3 Participants NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 160 mg Cont n=3 Participants NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in	JSR: 240 mg Cont n=3 Participants NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in
All-Collected Deaths On-treatment and post-treatment safety follow-up deaths	4 participants	6 participants	10 participants	6 participants	8 participants	4 participants	22 participants	9 participants	7 participants	9 participants	2 participants	2 participants	6 participants	4 participants	6 participants	4 participants	2 participants	0 participants	1 participants
All-Collected Deaths Survival follow-up deaths	3 participants	7 participants	3 participants	4 participants	12 participants	4 participants	22 participants	12 participants	8 participants	2 participants	3 participants	7 participants	8 participants	9 participants	7 participants	1 participants	—	—	1 participants
All-Collected Deaths All deaths	7 participants	13 participants	13 participants	10 participants	20 participants	8 participants	44 participants	21 participants	15 participants	11 participants	5 participants	9 participants	14 participants	13 participants	13 participants	5 participants	2 participants	0 participants	2 participants

Adverse Events

Part 1: RCC naïve 160 mg

Serious events: 3 serious events

Other events: 10 other events

Deaths: 4 deaths

Part 1: RCC naïve + Pre 240 mg

Serious events: 7 serious events

Other events: 22 other events

Deaths: 6 deaths

Part 1: Pancreatic 160 mg

Serious events: 9 serious events

Other events: 14 other events

Deaths: 10 deaths

Part 1: Urothelial 160 mg

Serious events: 7 serious events

Other events: 14 other events

Deaths: 6 deaths

Part 1: H-N naïve + Pre 160 mg

Serious events: 16 serious events

Other events: 25 other events

Deaths: 8 deaths

Part 1: H-N Pre 240 mg

Serious events: 5 serious events

Other events: 12 other events

Deaths: 4 deaths

Part 1: MSS CRC 160 mg

Serious events: 28 serious events

Other events: 52 other events

Deaths: 22 deaths

Part 1: TNBC 160 mg

Serious events: 14 serious events

Other events: 29 other events

Deaths: 9 deaths

Part 1: Melanoma naïve + Pre 160 mg

Serious events: 4 serious events

Other events: 14 other events

Deaths: 7 deaths

Part 1: DLBCL 160 mg

Serious events: 7 serious events

Other events: 13 other events

Deaths: 9 deaths

Part 1: DLBCL 240 mg

Serious events: 0 serious events

Other events: 5 other events

Deaths: 2 deaths

Part 1: mCRPC 240 mg

Serious events: 5 serious events

Other events: 14 other events

Deaths: 2 deaths

Part 2: NSCLC 160 mg Cont

Serious events: 11 serious events

Other events: 22 other events

Deaths: 6 deaths

Part 2: NSCLC 160 mg 2wk-on/2wk-off

Serious events: 9 serious events

Other events: 16 other events

Deaths: 4 deaths

Part 2: NSCLC 160 mg 1wk-on/1wk-off

Serious events: 7 serious events

Other events: 17 other events

Deaths: 6 deaths

Part 3: TNBC 160 mg Cont

Serious events: 3 serious events

Other events: 6 other events

Deaths: 4 deaths

JSR: 80 mg Cont

Serious events: 2 serious events

Other events: 3 other events

Deaths: 2 deaths

JSR: 160 mg Cont

Serious events: 1 serious events

Other events: 2 other events

Deaths: 0 deaths

JSR: 240 mg Cont

Serious events: 1 serious events

Other events: 3 other events

Deaths: 1 deaths

Part 1: RCC naïve 160 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 3 deaths

Part 1: RCC naïve + Pre 240 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 7 deaths

Part 1: Pancreatic 160 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 3 deaths

Part 1: Urothelial 160 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 4 deaths

Part 1: H-N naïve + Pre 160 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 12 deaths

Part 1: H-N Pre 240 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 4 deaths

Part 1: MSS CRC 160 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 22 deaths

Part 1: TNBC 160 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 12 deaths

Part 1: Melanoma naïve + Pre 160 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 8 deaths

Part 1: DLBCL 160 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 2 deaths

Part 1: DLBCL 240 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 3 deaths

Part 1: mCRPC 240 mg_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 7 deaths

Part 2: NSCLC 160 mg cont_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 8 deaths

Part 2: NSCLC 160 mg 2wk-on/2wk-off_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 9 deaths

Part 2: NSCLC 160 mg 1wk-on/1wk-off_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 7 deaths

Part 3: TNBC 160 mg cont_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 1 deaths

JSR: 80 mg cont_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

JSR: 160 mg cont_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

JSR: 240 mg cont_Survival Period

Serious events: 0 serious events

Other events: 0 other events

Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure	Part 1: RCC naïve 160 mg n=11 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: RCC naïve + Pre 240 mg n=23 participants at risk NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC), naïve and pretreated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: Pancreatic 160 mg n=14 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: Urothelial 160 mg n=14 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: H-N naïve + Pre 160 mg n=26 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC), naïve and pretreated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: H-N Pre 240 mg n=12 participants at risk NIR178 240 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: MSS CRC 160 mg n=58 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) and RAS wildtype, RAS mutant and RAS unknown status. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: TNBC 160 mg n=30 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: Melanoma naïve + Pre 160 mg n=16 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma, naïve and pretreated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: DLBCL 160 mg n=13 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL). Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: DLBCL 240 mg n=6 participants at risk NIR178 240 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL). Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: mCRPC 240 mg n=15 participants at risk NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 2: NSCLC 160 mg Cont n=22 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with non-small cell lung cancer (NSCLC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 participants at risk NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 participants at risk NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 3: TNBC 160 mg Cont n=6 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC). Safety data up to 150 days after last dose of NIR178+PDR001	JSR: 80 mg Cont n=3 participants at risk NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in. Safety data up to 150 days after last dose of NIR178+PDR001	JSR: 160 mg Cont n=3 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in. Safety data up to 150 days after last dose of NIR178+PDR001	JSR: 240 mg Cont n=3 participants at risk NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: RCC naïve 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: RCC naïve + Pre 240 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: Pancreatic 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: Urothelial 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: H-N naïve + Pre 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: H-N Pre 240 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: MSS CRC 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: TNBC 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: Melanoma naïve + Pre 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: DLBCL 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: DLBCL 240 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: mCRPC 240 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 2: NSCLC 160 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 2: NSCLC 160 mg 2wk-on/2wk-off_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 2: NSCLC 160 mg 1wk-on/1wk-off_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 3: TNBC 160 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	JSR: 80 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	JSR: 160 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	JSR: 240 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.
Blood and lymphatic system disorders Anaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Blood and lymphatic system disorders Neutropenia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Cardiac failure	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Atrial tachycardia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Myocardial infarction	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Autoimmune myocarditis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Pericardial effusion	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Supraventricular tachycardia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Endocrine disorders Adrenal insufficiency	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Endocrine disorders Hyperthyroidism	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Eye disorders Blindness	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Eye disorders Gaze palsy	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Abdominal pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Ascites	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Colonic fistula	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Constipation	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Diarrhoea	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Duodenal ulcer	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Dysphagia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Ileus	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Intestinal obstruction	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Nausea	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Pancreatitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Vomiting	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Chest pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Disease progression	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Face oedema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Fatigue	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders General physical health deterioration	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Generalised oedema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Oedema peripheral	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Pyrexia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Autoimmune hepatitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Cholangitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Cholecystitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Hepatic failure	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Hepatic haemorrhage	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Hepatitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Immune-mediated hepatitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Liver disorder	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Bronchitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Cellulitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Encephalitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of the tongue	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Enterocolitis infectious	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Herpes zoster	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Influenza	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Large intestine infection	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Peritonitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Pleural infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Cerebral infarction	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Pneumonia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour haemorrhage	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Pneumonia aspiration	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Scrotal abscess	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Sepsis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Urinary tract infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Urogenital infection bacterial	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Vascular device infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Injury, poisoning and procedural complications Fall	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Injury, poisoning and procedural complications Multiple injuries	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Injury, poisoning and procedural complications Overdose	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Alanine aminotransferase increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Amylase increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Aspartate aminotransferase increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood bilirubin increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood creatine phosphokinase increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood creatinine increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Electrocardiogram QT prolonged	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations General physical condition abnormal	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Hepatic enzyme increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Lipase increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Troponin I increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hypervolaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Autoimmune myositis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Sacral pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to meninges	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pulmonary tumour thrombotic microangiopathy	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Cerebral haemorrhage	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Cerebrospinal fluid leakage	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Cerebrovascular accident	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Migraine	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Paraesthesia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Acute kidney injury	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Seizure	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Spinal cord compression	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Syncope	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Haematuria	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Nephrolithiasis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Renal impairment	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Female genital tract fistula	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Peyronie's disease	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Dyspnoea	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Hydrothorax	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Mediastinal disorder	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Pulmonary haemorrhage	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Erythema multiforme	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Rash	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Stevens-Johnson syndrome	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Aortic aneurysm	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.

Other adverse events

Other adverse events
Measure	Part 1: RCC naïve 160 mg n=11 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC) who had not been previously treated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: RCC naïve + Pre 240 mg n=23 participants at risk NIR178 240 mg twice daily continuous in combination with PDR001 in patients with renal cell carcinoma (RCC), naïve and pretreated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: Pancreatic 160 mg n=14 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with pancreatic cancer. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: Urothelial 160 mg n=14 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with urothelial cancer. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: H-N naïve + Pre 160 mg n=26 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC), naïve and pretreated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: H-N Pre 240 mg n=12 participants at risk NIR178 240 mg twice daily continuous in combination with PDR001 in patients with squamous cell carcinoma of head and neck (HNSCC) who had been pretreated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: MSS CRC 160 mg n=58 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with microsatellite stable colorectal cancer (MSS CRC) and RAS wildtype, RAS mutant and RAS unknown status. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: TNBC 160 mg n=30 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: Melanoma naïve + Pre 160 mg n=16 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with cutaneous melanoma, naïve and pretreated with immuno-oncology therapy. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: DLBCL 160 mg n=13 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL). Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: DLBCL 240 mg n=6 participants at risk NIR178 240 mg twice daily continuous in combination with PDR001 in patients with diffuse large B-cell lymphoma (DLBCL). Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: mCRPC 240 mg n=15 participants at risk NIR178 240 mg twice daily continuous in combination with PDR001 in patients with metastatic castration resistant prostate cancer (mCRPC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 2: NSCLC 160 mg Cont n=22 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with non-small cell lung cancer (NSCLC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 2: NSCLC 160 mg 2wk-on/2wk-off n=20 participants at risk NIR178 160 mg twice daily 2 weeks on/2 weeks off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 2: NSCLC 160 mg 1wk-on/1wk-off n=20 participants at risk NIR178 160 mg twice daily 1 week on/1 week off in combination with PDR001 in patients with non-small cell lung cancer (NSCLC). Safety data up to 150 days after last dose of NIR178+PDR001	Part 3: TNBC 160 mg Cont n=6 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 in patients with triple negative breast cancer (TNBC). Safety data up to 150 days after last dose of NIR178+PDR001	JSR: 80 mg Cont n=3 participants at risk NIR178 80 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in. Safety data up to 150 days after last dose of NIR178+PDR001	JSR: 160 mg Cont n=3 participants at risk NIR178 160 mg twice daily continuous in combination with PDR001 (starting Cycle 2 Day 1) in the Japan safety run-in. Safety data up to 150 days after last dose of NIR178+PDR001	JSR: 240 mg Cont n=3 participants at risk NIR178 140 mg twice daily continuous in combination with PDR001 (starting Cycle 1 Day 1) in the Japan safety run-in. Safety data up to 150 days after last dose of NIR178+PDR001	Part 1: RCC naïve 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: RCC naïve + Pre 240 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: Pancreatic 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: Urothelial 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: H-N naïve + Pre 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: H-N Pre 240 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: MSS CRC 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: TNBC 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: Melanoma naïve + Pre 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: DLBCL 160 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: DLBCL 240 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 1: mCRPC 240 mg_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 2: NSCLC 160 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 2: NSCLC 160 mg 2wk-on/2wk-off_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 2: NSCLC 160 mg 1wk-on/1wk-off_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	Part 3: TNBC 160 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	JSR: 80 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	JSR: 160 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.	JSR: 240 mg cont_Survival Period Deaths collected in the survival follow-up period (starting from Day 151 after last dose of NIR178+PDR001). No AEs were collected during this period.
Blood and lymphatic system disorders Anaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	35.7% 5/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	19.2% 5/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.6% 5/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 4/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	18.8% 3/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	23.1% 3/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Blood and lymphatic system disorders Leukopenia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Blood and lymphatic system disorders Lymphadenitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Blood and lymphatic system disorders Neutropenia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	23.1% 3/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Toothache	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Vomiting	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 4/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.7% 12/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 5/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	22.7% 5/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Atrial fibrillation	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Bradycardia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Extrasystoles	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Cardiac failure congestive	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Coronary artery disease	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Palpitations	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Pericardial effusion	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Sinus bradycardia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Sinus tachycardia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Cardiac disorders Tachycardia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Ear and labyrinth disorders Vertigo	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Endocrine disorders Adrenal insufficiency	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Endocrine disorders Hyperthyroidism	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Endocrine disorders Hypothyroidism	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.6% 5/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Endocrine disorders Lymphocytic hypophysitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Eye disorders Cataract	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Eye disorders Photopsia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Eye disorders Vision blurred	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Abdominal distension	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.0% 3/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Abdominal pain	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	28.6% 4/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.5% 9/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 2/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.3% 6/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Ascites	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Constipation	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	30.4% 7/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 4/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.5% 9/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	23.1% 3/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	36.4% 8/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	40.0% 8/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 2/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Dental caries	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Diarrhoea	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	34.8% 8/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	28.6% 4/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 4/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.7% 12/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 3/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	18.2% 4/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	50.0% 3/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Dry mouth	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Dyspepsia	18.2% 2/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Dysphagia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 4/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Gastrointestinal disorder	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Faeces soft	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Flatulence	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	19.2% 5/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.6% 5/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Haemorrhoids	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Haematochezia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Ileus	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Nausea	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.7% 5/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	28.6% 4/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	35.7% 5/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	23.1% 6/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 2/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	22.4% 13/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	30.0% 9/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	25.0% 4/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 5/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	22.7% 5/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	66.7% 4/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Retching	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Gastrointestinal disorders Stomatitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Administration site bruise	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Asthenia	18.2% 2/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.7% 5/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 5/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	25.0% 4/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 2/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Axillary pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Catheter site oedema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Chest discomfort	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Chest pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 4/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Chills	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Discomfort	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Face oedema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Fatigue	36.4% 4/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.7% 5/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	35.7% 5/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	42.3% 11/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	25.0% 3/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	34.5% 20/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 10/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	18.8% 3/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	26.7% 4/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	50.0% 11/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	30.0% 6/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	25.0% 5/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	50.0% 3/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Feeling of body temperature change	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Gait disturbance	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders General physical health deterioration	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations SARS-CoV-2 test negative	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Influenza like illness	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Malaise	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Non-cardiac chest pain	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 2/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Oedema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Oedema peripheral	18.2% 2/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.6% 5/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	12.5% 2/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Peripheral swelling	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Pyrexia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	28.6% 4/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 4/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.5% 9/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	30.0% 9/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	30.8% 4/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
General disorders Swelling face	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Cholestasis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Hepatic failure	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Hepatic steatosis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Hepatitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Hypertransaminasaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Immune-mediated hepatitis	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Hepatobiliary disorders Jaundice	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Abdominal abscess	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Body tinea	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations COVID-19	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Device related infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Diarrhoea infectious	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Escherichia sepsis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Eye infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Gastroenteritis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Herpes zoster	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Influenza	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Nasopharyngitis	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Oesophageal candidiasis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Oral candidiasis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Pharyngitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Pneumonia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.6% 3/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Rash pustular	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Tinea versicolour	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Tonsillitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Tracheitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Upper respiratory tract infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Urinary tract infection	18.2% 2/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.6% 5/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Urinary tract infection enterococcal	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Urogenital infection bacterial	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Vaginal infection	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Infections and infestations Viral infection	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Injury, poisoning and procedural complications Fall	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Injury, poisoning and procedural complications Wound complication	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Injury, poisoning and procedural complications Wound necrosis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations SARS-CoV-2 test positive	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Alanine aminotransferase increased	18.2% 2/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	19.0% 11/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	30.0% 9/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 3/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Amylase increased	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	26.7% 4/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Aspartate aminotransferase increased	18.2% 2/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	24.1% 14/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	30.0% 9/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 3/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Bilirubin conjugated increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood alkaline phosphatase increased	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood bilirubin increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood creatine phosphokinase increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Eosinophil count increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood creatinine increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	12.5% 2/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood lactate dehydrogenase increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood phosphorus increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Blood thyroid stimulating hormone increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations C-reactive protein increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Electrocardiogram QT prolonged	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Gamma-glutamyltransferase increased	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.3% 6/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Haemoglobin decreased	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Human chorionic gonadotropin increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations International normalised ratio increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Lipase increased	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	26.7% 4/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Lymphocyte count decreased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	66.7% 2/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Oxygen saturation decreased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Platelet count decreased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Transaminases increased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Investigations Weight decreased	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Cachexia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Decreased appetite	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.0% 3/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	50.0% 7/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	35.7% 5/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	23.1% 6/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	29.3% 17/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 4/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	12.5% 2/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	23.1% 3/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	27.3% 6/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	25.0% 5/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	66.7% 2/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Dehydration	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Glucose tolerance impaired	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hypercalcaemia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.0% 3/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.6% 3/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hyperglycaemia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hyperlipasaemia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hyperuricaemia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hypoalbuminaemia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	23.1% 3/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Iron deficiency	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Malnutrition	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Obesity	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Tumour lysis syndrome	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Vitamin B12 deficiency	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Metabolism and nutrition disorders Vitamin D deficiency	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Amyotrophy	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Arthralgia	27.3% 3/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 4/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.5% 9/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	26.7% 8/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.6% 3/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 2/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Back pain	27.3% 3/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.7% 5/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.4% 3/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.6% 5/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 4/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 3/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.6% 3/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Bone pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Fracture pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Joint stiffness	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Mobility decreased	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Muscle atrophy	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Muscle spasms	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.6% 5/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Myalgia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 2/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 4/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 3/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Osteoarthritis	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	18.8% 3/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Pain in jaw	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Musculoskeletal and connective tissue disorders Trismus	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Hypergammaglobulinaemia benign monoclonal	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm progression	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Hypoaesthesia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Seborrhoeic keratosis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Amnesia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Anosmia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Aphasia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Autonomic nervous system imbalance	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Dizziness	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	35.7% 5/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 4/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Dysaesthesia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Dysgeusia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Headache	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 2/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 4/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	18.2% 4/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Migraine	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Neuropathy peripheral	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Paraesthesia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Presyncope	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Sciatica	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Seizure	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Somnolence	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Taste disorder	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Nervous system disorders Tremor	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Anxiety	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Confusional state	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Depression	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Hallucination	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Insomnia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.0% 3/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.9% 4/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.6% 3/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Mood altered	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Panic disorder	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Restlessness	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Sleep disorder	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Psychiatric disorders Stress	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Acute kidney injury	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Azotaemia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Bladder pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Chronic kidney disease	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Dysuria	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Haematuria	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Leukocyturia	18.2% 2/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Nocturia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Urethral pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Renal and urinary disorders Urinary retention	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Balanoposthitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Benign prostatic hyperplasia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Breast oedema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Breast pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 2/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Intermenstrual bleeding	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Pelvic pain	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Peyronie's disease	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Reproductive system and breast disorders Vaginal discharge	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	28.6% 4/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 4/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	19.0% 11/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 10/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	27.3% 6/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Dyspnoea	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	28.6% 4/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.8% 8/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 6/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	22.7% 5/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	25.0% 5/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	20.0% 4/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Rhinalgia	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.6% 3/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Sputum retention	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Lymphoedema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Respiratory, thoracic and mediastinal disorders Tonsillar erythema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Acne	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Alopecia	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Decubitus ulcer	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Raynaud's phenomenon	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Dry skin	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Eczema	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	9.1% 2/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Hyperkeratosis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Intertrigo	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Pemphigoid	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Pruritus	27.3% 3/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.7% 2/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 2/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.8% 8/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 3/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	12.5% 2/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	22.7% 5/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.0% 3/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Rash	18.2% 2/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	21.7% 5/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	11.5% 3/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.2% 3/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	15.4% 2/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	26.7% 4/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.6% 3/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Rash pruritic	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	10.0% 2/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Scar pain	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Seborrhoeic dermatitis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Skin exfoliation	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Skin and subcutaneous tissue disorders Vitiligo	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.2% 1/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Angiopathy	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Flushing	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Haematoma	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.3% 1/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Hot flush	9.1% 1/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	1.7% 1/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 1/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	16.7% 1/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Hypertension	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.3% 1/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.8% 1/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	3.4% 2/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	6.7% 2/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	13.3% 2/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	33.3% 1/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Hypotension	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.1% 1/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	8.3% 1/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	7.7% 1/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	4.5% 1/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	5.0% 1/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.
Vascular disorders Superficial vein thrombosis	0.00% 0/11 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/23 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	14.3% 2/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/14 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/26 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/12 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/58 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/30 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/16 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/13 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/15 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/22 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/20 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/6 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	0.00% 0/3 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.	— 0/0 • On-treatment and post-treatment safety follow-up: from first dose of study treatment to 150 days after last dose of NIR178+PDR001, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (Japan safety run-in; JSR). Deaths in survival period: from 151 days after last dose of NIR178+PDR001 until end of study, up to 4.3 years (Part 1), 5.1 years (Part 2), 0.9 years (Part 3) and 0.9 years (JSR). Deaths in the survival period are not considered Adverse Events (AEs). No AEs were collected in the survival period.

Additional Information

Study Director

Novartis Pharmaceuticals

Phone: 862-778-8300

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. Novartis does not prohibit any investigator from publishing. Any publications from a single site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
Publication restrictions are in place

Restriction type: OTHER